The FDA granted fast-track status to Genzyme's alemtuzumab as a treatment for relapsing-remitting multiple sclerosis. The drug might rival Biogen Idec's MS treatments if it receives approval.
Published in Brief:
|Health Services Researcher||
|Chief Executive Officer||
Center for Improving Value in Healthcare
|Senior director risk adjustor and coding doc||
|Associate Director, Promotion Integrity||
|Chief Medical Officer||